Bristol-Myers Squibb Company

LSE:0R1F Stock Report

Market Cap: US$102.9b

Bristol-Myers Squibb Valuation

Is 0R1F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0R1F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$134.43
Fair Value
62.7% undervalued intrinsic discount
22
Number of Analysts

Below Fair Value: 0R1F ($50.17) is trading below our estimate of fair value ($134.43)

Significantly Below Fair Value: 0R1F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0R1F?

Key metric: As 0R1F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0R1F. This is calculated by dividing 0R1F's market cap by their current earnings.
What is 0R1F's PE Ratio?
PE Ratio19x
EarningsUS$5.42b
Market CapUS$102.91b

Price to Earnings Ratio vs Peers

How does 0R1F's PE Ratio compare to its peers?

The above table shows the PE ratio for 0R1F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.1x
GSK GSK
18.6x16.6%UK£58.6b
HLN Haleon
24.9x6.9%UK£35.9b
AZN AstraZeneca
28.5x14.5%UK£166.8b
HIK Hikma Pharmaceuticals
16.4x11.6%UK£4.4b
0R1F Bristol-Myers Squibb
19x7.5%US$102.9b

Price-To-Earnings vs Peers: 0R1F is good value based on its Price-To-Earnings Ratio (19x) compared to the peer average (22.1x).

Price to Earnings Ratio vs Industry

How does 0R1F's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0R1F 19.0xIndustry Avg. 21.9xNo. of Companies9PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0R1F is good value based on its Price-To-Earnings Ratio (19x) compared to the European Pharmaceuticals industry average (21.9x).

Price to Earnings Ratio vs Fair Ratio

What is 0R1F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0R1F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19x
Fair PE Ratio40.7x

Price-To-Earnings vs Fair Ratio: 0R1F is good value based on its Price-To-Earnings Ratio (19x) compared to the estimated Fair Price-To-Earnings Ratio (40.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0R1F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$50.17
US$57.20
+14.0%
14.0%US$68.00US$36.00n/a22
Apr ’26US$59.60
US$61.24
+2.8%
11.9%US$70.00US$37.00n/a21
Mar ’26US$58.71
US$61.24
+4.3%
11.9%US$70.00US$37.00n/a21
Feb ’26US$58.79
US$61.48
+4.6%
12.2%US$73.00US$39.00n/a21
Jan ’26US$56.34
US$60.91
+8.1%
12.1%US$73.00US$39.00n/a21
Dec ’25US$59.22
US$60.43
+2.1%
12.0%US$73.00US$39.00n/a21
Nov ’25US$54.73
US$54.51
-0.4%
12.4%US$64.00US$36.00n/a22
Oct ’25US$52.71
US$53.86
+2.2%
14.7%US$75.00US$37.00n/a21
Sep ’25US$50.05
US$53.34
+6.6%
14.9%US$75.00US$37.00n/a21
Aug ’25US$48.18
US$52.01
+8.0%
16.2%US$75.00US$37.00n/a22
Jul ’25US$41.34
US$53.19
+28.7%
16.7%US$75.00US$37.00n/a22
Jun ’25US$41.05
US$53.19
+29.6%
16.7%US$75.00US$37.00n/a22
May ’25US$44.00
US$53.54
+21.7%
15.8%US$75.00US$37.00US$49.7423
Apr ’25US$54.32
US$56.50
+4.0%
13.3%US$75.00US$41.00US$59.6023
Mar ’25US$50.64
US$56.70
+12.0%
15.8%US$85.00US$41.00US$58.7122
Feb ’25US$48.61
US$60.66
+24.8%
16.7%US$85.00US$42.00US$58.7923
Jan ’25US$51.15
US$61.92
+21.1%
16.5%US$85.00US$42.00US$56.3423
Dec ’24US$49.78
US$64.13
+28.8%
17.0%US$90.00US$50.00US$59.2224
Nov ’24US$51.65
US$65.60
+27.0%
16.0%US$90.00US$50.00US$54.7323
Oct ’24US$58.01
US$72.47
+24.9%
13.0%US$90.00US$55.00US$52.7123
Sep ’24US$62.04
US$72.83
+17.4%
13.4%US$90.00US$56.00US$50.0524
Aug ’24US$61.47
US$73.21
+19.1%
13.6%US$92.00US$56.00US$48.1824
Jul ’24US$64.20
US$78.64
+22.5%
12.4%US$92.00US$59.00US$41.3422
Jun ’24US$64.60
US$79.05
+22.4%
12.4%US$92.00US$59.00US$41.0521
May ’24US$67.09
US$78.74
+17.4%
11.8%US$92.00US$59.00US$44.0021
AnalystConsensusTarget
Consensus Narrative from 22 Analysts
US$56.75
Fair Value
11.6% undervalued intrinsic discount
22
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/04 04:46
End of Day Share Price 2025/05/02 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bristol-Myers Squibb Company is covered by 46 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Charles ButlerBarclays